A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
← catalyst calendarNCT05804669 · readout ≤ 73 d
Sponsored by Crinetics Pharmaceuticals Inc. (industry) · CRNX — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
19actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-10-12 | actual | When the study began enrolling |
| Primary completion | Oct 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2023-04-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Cushing Syndrome
- Cushing Disease
- Ectopic ACTH Syndrome
Intervention
- Drug: atumelnant
Primary outcomes
what the primary-completion date above is the date OFProportion of participants with treatment emergent adverse events (TEAEs)
measured Up to Day 15
Proportion of participants with adrenal insufficiency
measured Up to Day 15
Proportion of participants with safety findings determined by laboratory testing
measured Up to Day 15
Assessment of the maximum observed plasma concentration of CRN04894
measured Up to Day 15
Assessment of the time to achieve maximum observed plasma concentration of CRN04894
measured Up to Day 15
Assessment of the plasma area under the curve of CRN04894
measured Up to Day 15
Permalink · CRNX's whole pipeline · Catalyst calendar · Every registered study · What changed